O IP SA COME FORM

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 1 of 4

| ATTORNEY DOCKET NO. | SERIAL NO. |
|--|------------|
| 3124/9A/US (Pfizer Ref. 31134A/USA) | 10/730,403 |
| APPLICANT | |
| Thomas E. Barta et al. | |
| FILING DATE | GROUP |
| December 8, 2003 | 1625 |

| U.S. PATENT DO | · · · · · · | | · | | 1 | |
|--|------------------------|---|-----------|------------------|--------------------|------------------------------|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Name | Class/ Subclass | (If appropriate) Filing Date |
| 1. | ce | 4,595,700 | 6/17/1986 | Donald et al. | 514/616 | |
| · 2. | | 5,932,595 | 8/3/1999 | Bender et al. | 514/317 | |
| 3. | | 6,013,649 | 1/11/2000 | Freskos et al. | 514/237.8 | |
| 4. | | 6,300,514 | 10/9/2001 | Takahashi et al. | 560/17 | |
| 5. (Office action and notices of allowance enclosed) | | 6,541,489, including 12/17/01 Office action, 5/16/02 notice of allowance, and 11/08/02 notice of allowance | 4/1/2003 | Barta et al. | 514/330 | 7/31/2000 |
| 6. (Office action and notice of allowance enclosed) | | 6,689,794, including 4/11/03 Office action and 5/28/03 notice of allowance | 2/10/2004 | Barta et al. | 514/318 | 05/10/2002 |
| 7. (Office action and notice of allowance enclosed) | | 6,750,233, including 11/18/02 Office action and 5/09/03 notice of allowance | 6/15/2004 | Barta et al. | 514/336 | 09/17/2001 |
| 8. (pending claims enclosed) | | Publ. No. 2004-0024024 (Appl. No. 10/291,983), including pending claims | | Freskos et al. | 514/326 | 11/12/2002 |
| 9. (notice of allowance and allowed claims enclosed) | | Publ. No. 2004-0048852 (Appl. No. 10/337,942), including allowed claims and 2/13/04 notice of allowance | | Barta et al. | 514/317 | 01/07/2003 |
| 10. (notice of allowance and allowed claims enclosed) | | Publ. No. 2004-0110805 (Appl. No. 10/657,034), including allowed claims and 7/21/04 notice of allowance | | Freskos et al. | 514/256 | 09/05/2003 |
| 11. (pending claims enclosed) | 2 | Publ. No. 2004-0235818 (Appl. No. 10/747,796), including pending claims | | Barta et al. | 514/315 | 12/29/2003 |

| | · | | | | |
|-----------|----|------------------|------|-------------|---|
| Examiner: | Oh | Date Considered: | 2/23 | 106 | |
| | | | | | _ |

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 2 of 4

| ATTORNEY DOCKET NO. | SERIAL NO. | |
|--|------------|--|
| 3124/9A/US (Pfizer Ref. 31134A/USA) | 10/730,403 | |
| APPLICANT | | |
| Thomas E. Barta et al. | | |
| FILING DATE | GROUP | |
| December 8, 2003 | 1625 | |

| U.S. PATÉNT D | OCUMENT | 5 | | | \$ | |
|-------------------|------------------------|--|------|----------------|--------------------|------------------------------|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Name | Class/ Subclass | (If appropriate) Filing Date |
| 12. (enclosed) | w | Pending claims from Appl. No. 10/992,483 | | Freskos et al. | ТВА | 11/07/2004 |

| FOREIGN P | ATENT DOCU | JMENTS | | | | | <i>.</i> * |
|---|------------------------|--------------------|------------|---------|--------------------|-----------------|------------|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes | on No |
| 13. | w | EP 0 266 182 | 5/4/1988 | Europe | C07D 307/32 | 1.00 | T |
| . 14. | | EP 0 606 046 | 7/13/1994 | Europe | C07D 213/42 | | |
| 15. | | EP 0 780 386 | 6/25/1997 | Europe | C07D 309/08 | | |
| 16. | | EP 0 930 067 | 7/21/1999 | Europe | A61K 31/40 | | |
| 17. | | EP 1 081 137 | 3/7/2001 | Europe | C07D 211/96 | | |
| 18. (partial translation enclosed) | | JP 4-338331 | 11/25/1992 | Japan | A61K 31/365 | partial | |
| 19. | | WO 90/05719 | 5/31/1990 | PCT | C07C 323/62 | | |
| 20. | | WO 93/20047 | 10/14/1993 | PCT | C07C 317/44 | | |
| 21. | | WO 94/02466 | 2/3/1994 | PCT | C07D 221/14 | | |
| 22. | | WO 94/24140 | 10/27/1994 | PCT | C07H 13/04 | | |
| 23. | | WO 95/09841 | 4/13/1995 | PCT | C07C 323/60 | | |
| 24. | | WO 95/13289 | 5/18/1995 | PCT | C07K 5/062 | | |
| 25. | w | WO 95/29892 | 11/09/1995 | PCT | C07D 207/327 | | |

| Examiner: | ch | Date Considered: | 2-3 | 106 | |
|-----------|----|------------------|-----|-----|--|
| | T. | | | | |

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 4

| ATTORNEY DOCKET NO. | SERIAL NO. | |
|--|------------|--|
| 3124/9A/US (Pfizer Ref. 31134A/USA) | 10/730,403 | |
| APPLICANT | | |
| Thomas E. Barta et al. | | |
| FILING DATE | GROUP | |
| December 8, 2003 | 1625 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|------------------------|--------------------|------------|---------|--------------------|-----------------|-----------|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translat Yes | ion No |
| 26. | a | WO 96/06074 | 2/29/1996 | PCT | C07C 259/06 | | |
| · 27. | | WO 96/11209 | 4/18/1996 | PCT | C07K 5/06 | | |
| , 28. | | WO 97/20824 | 6/12/1997 | PCT | C07D 241/04 | | |
| 29. | | WO 97/24117 | 7/10/1997 | PCT | A61K 31/19 | | |
| 30. | | WO 98/37877 | 9/3/1998 | PCT | A61K 31/16 | | |
| - 31. | | WO 98/38163 | 9/3/1998 | PCT | C07C 323/60 | | |
| 32. | | WO 99/09000 | 2/25/1999 | PCT | C07C 235/00 | | |
| 33. | | WO 99/25687 | 5/27/1999 | PCT | C07D 211/66 | | |
| 34. | | WO 99/42436 | 8/26/1999 | PCT | C07C . 239/14 | | |
| 35. | | WO 00/46221 | 8/10/2000 | PCT | C07D 405/12 | | |
| 36. | | WO 00/50396 | 8/31/2000 | PCT | C07D 211/66 | | |
| 37. | | WO 00/59874 | 10/12/2000 | PCT | C07C 259/06 | | |
| 38. | a | WO 00/69821 | 11/23/2000 | PCT | C07D 211/66 | | |

| OTHER | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | | | | | |
|----------------|--|--|--|--|--|--|--|
| Ref. Desig. | Examiner's Initials | | | | | | |
| 39. | a | Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998). | | | | | |
| 40. | a | Dack, et al., Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors, CA 131:44740 (1999) [CA Plus Accession No. 1999:388166] | | | | | |

| Examiner: Ch | ^ | Date Considered: | 2/23/06 |
|--------------|---|------------------|---------|
| | | | |

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 4 of 4

| ATTORNEY DOCKET NO. | SERIAL NO. |
|--|------------|
| 3124/9A/US (Pfizer Ref. 31134A/USA) | 10/730,403 |
| APPLICANT | |
| Thomas E. Barta et al. | |
| FILING DATE | GROUP |
| December 8, 2003 | 1625 |

| Ref. Desig. | Examiner's Initials | |
|----------------|---------------------|--|
| 41. | le | Denis et al., Matrix metalloproteinase inhibitors: Present achievements and future prospects, INVEST. NEW DRUGS, 15:175-185 (1997). |
| 42. | | Gearing et al., Processing of tumour necrosis factor-a precursor by metalloproteinases, NATURE, 370:555-557 (1994). |
| 43. | | Kenyon et al., A model of angiogenesis in the mouse cornea, INVEST. OPHTHALMOL. VIS. SCI., 37(8):1625-1632 (1996). |
| 44. | | Knight et al., A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, FEBS LETT., 296(3):263-266 (1992). |
| • 45. | | Luckow et al., Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli, J. VIROL., 67:4566-4579 (1993). |
| ` 46. | | McClure, et al., Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases, CA 131:125454 (1999) [CA Plus Accession No. 1999:468334] |
| 47. | | McGeehan et al., Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor, NATURE, 370:558-561 (1994). |
| 48. | | Mitchell et al., Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage, J. CLIN. INVEST. 97(3):761-768 (1996). |
| 49. | | Rasmussen et al., Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat, PHARMACOL. THER., 75(1):69-75 (1997). |
| 50. | | Reboul et al., The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes, J. CLIN. INVEST., 97(9):2011-2019 (1996). |
| 51. | | Schwartz et al., Synthetic inhibitors of bacterial and mammalian interstitial collagenases, PROG. IN MED CHEM., 29:271-334 (1992). |
| 52. | | Tang, B. L., ADAMTS: A Novel Family of Extracellular Matrix Proteases, INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001). |
| 53. | 1 | Woessner, J.F., "The Matrix Metalloprotease Family" in Matrix Metalloproteinases, pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998). |

| Examiner: | Clay | Date Considered: | 2/23/06 |
|-----------|------|------------------|---------|
| | - // | • | |